Scientific Zambon Pharma July 18, 2023 Zambon Presents Results from the Two Phase 3 PROMIS Studies of CMS I-neb in Patients with Non-Cystic Fibrosis Bronchiectasis at World Bronchiectasis Conference 2023
Scientific Zambon Pharma May 23, 2023 Zambon Presents Survey Results Showcasing Humanistic Impact of Bronchiolitis Obliterans Syndrome on Patients in the United States
Scientific Zambon Pharma May 9, 2023 Zambon Announces New Data Highlighting Lifetime Burden of Illness in U.S. Patients with Bronchiolitis Obliterans Syndrome at ISPOR 2023
Scientific Zambon Pharma May 2, 2023 Zambon Completes Enrollment in Phase 3 Clinical Development Program Evaluating Liposomal Cyclosporine A for Inhalation (L-CsA-i) in Patients with Bronchiolitis Obliterans Syndrome (BOS)
Scientific Zambon Pharma April 21, 2022 Zambon Receives U.S. FDA Breakthrough Therapy Designation for CMS I-neb® in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFB)
Scientific Zambon Pharma February 21, 2022 COVID-19. A probiotic formula reduces symptom duration and viral load, increases antibodies, and improves remission rate among patients with mild symptoms
Scientific Zambon Pharma September 8, 2021 Positive Results from Phase 3 PROMIS-I Study of CMS I-neb® in Patients with Non-Cystic Fibrosis Bronchiectasis Presented at European Respiratory Society (ERS) Annual Meeting
Scientific Zambon Pharma May 12, 2021 Newron and Zambon sign agreement for potentially pivotal study with safinamide in Parkinson’s disease patient
